

**CURRICULUM VITAE**

**Omeed Moaven, MD, FACS**

**Current Title:** Assistant Professor of Clinical Surgery

**Business Address:** LSU Health – New Orleans

School of Medicine

Department of Surgery

Division of Surgical Oncology

1542 Tulane Avenue, Room 734

New Orleans, LA 70112

**Business Telephone**

**and Fax:**  (504) 568-4750 p; (504) 568-4633 (f)

**Business email Address:** [omoave@lsuhsc.edu](mailto:omoave@lsuhsc.edu)

**Citizenship:** United States of America

**Education**

**Medical:** M.D., Medicine, Mashhad University of Medical Sciences, Mashhad, Iran (10/00-10/07)

**Internship:** Massachusetts General Hospital (06/12-06/13)

**Residency:** Massachusetts General Hospital (06/13-06/14)

University of Alabama, Birmingham (06/15–06/18)

**Post-Doctoral**

**Fellowships:** Hodin Lab, Dep of Surgery, Massachusetts General Hospital/Harvard Medical School (01/11-06/12)

Tanabe Lab, Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School (06/14-06/15)

**Clinical Fellowships:** Complex General Surgical Oncology fellowship, Wake Forest University (08/18–07/20)

**Certification:** American Board of Surgery Certification, Complex General Surgical Oncology (2021)

American Board of Surgery Certification, General Surgery (2018)

**Licensure:**

Louisiana State Board of Medical Examiners, #330558, 04/2022 - present

Louisiana Board of Pharmacy, #CDS.062339-MD, 04/2022 - present

**Academic, Professional, and Research Appointments**

**Academic Appointment:**

LSU Health, School of Medicine, Department of Surgery, Department of Interdisciplinary Oncology, Assistant Professor, 06/22 – present

Mayo Clinic, Florida, Department of Surgery, Department of Cancer Biology, Assistant Professor, 08/20

**Professional Appointment:**

Surgical Oncologist, University Medical Center (UMC)

Senior Associate Consultant, Mayo Clinic, Florida

**Research Appointment:**

Louisiana Cancer Research Center (LCRC)

**Membership in Professional Organizations:**

2008 American Association for Cancer Research (AACR)

2011 American College of Surgeons (ACS)

2011 American Society of Clinical Oncology (ASCO)

2016 Society of Surgical Oncology (SSO)

2016 Association of Academic Surgery (AAS)

2018 (Committee member) Americas Hepatopancreaticobiliary Association (AHPBA)

2020 Pancreas Club

2021 (Committee member) Alliance for Clinical Trials

2022 Society of Immunotherapy for Cancer

**Awards and Honors:**

1998 Silver Medal, National Chemistry Olympiad, Ministry of Education, Iran

2008 Scholar-in-Training Award, American Association for Cancer Research (AACR) International Conference on "Advances in Cancer Research: From the Laboratory to the Clinic"

2009 Best research study, (In vitro analysis of immune response of the T lymphocytes primed with the Dendritic Cells loaded with total tumor mRNA for immunotherapy of esophageal cancer – Principal Contributor), Khorasan Razavi Annual Research and Technology Festival, Iran

2019 First place, Cancer paper competition, American College of Surgeons North and South Carolina Chapter “Health-Related Quality of Life after Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.”

2019 Deal Fund Travel Award, Wake Forest Baptist Comprehensive Cancer Center

2020 Advanced Cancer Therapies 2020 SSO/ACPMP Travel Award

2021 Norma Lee and Morton Funger Clinician Career Development Award in Pancreatic Cancer Research, Mayo Clinic

**TEACHING EXPERIENCE AND RESPONSIBILITIES**

**Departmental/Interdisciplinary Teaching Conferences**

HPB Journal Club (target audience, residents), Mayo Clinic, Florida

**Undergraduate, Medical, or Graduate Students Trained:**

Resident Mentorship

2020- Rebecca Shuford Research

2019-2021 Megan Lundy Research

2019-2021 Nima Zarandi Research

**Thesis and Dissertation Committees:**

Ph.D. Thesis Advisory Committee- Khandoker U. Ferdous, PhD Candidate (University of Arkansas

**RESEARCH AND SCHOLARSHIP**

The translational research I conduct in my lab is mainly focused on optimizing immuno-oncology approaches in the treatment of pancreatic cancer.We attempt to enhance the immune response and achieve synergistic anti-tumor activity by combining oncolytic virotherapy with various immunotherapeutic modalities in immunologically “cold’” tumors. We bioengineer oncolytic viruses to overcome therapeutic challenges in pancreatic cancer. These novel designs target the physical barrier and immunosuppressive tumor microenvironment in pancreatic cancer.

**Grants and Contracts**

**Funded:**

Norma Lee and Morton Funger Clinician Career Development Award in Pancreatic Cancer Research, Mayo Clinic (2021). PI (50% effort) 150,000$

**Journal Publications**

**Refereed:**

1. Abbaszadegan MR, **Moaven O**, Sima H, Ghafarzadegan K, A’rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaeeli-Shandiz E, Dadkhah E. p16 Promoter Hypermethylation: A Useful Serum Marker for Early Detection of Gastric Cancer. *World J* *Gastroenterol* 2008 Apr 7; 14(13):2055-60
2. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh Kermani A, **Moaven O**, Bahrani M. Expression of Cell Adhesion Molecule CD44 in Gastric Adenocarcinoma and its Correlation with Clinicopathological Characteristics and Survival. *World J Gastroenterol* 2008 Nov 7; 14(41):6376-81.
3. ZaliMR, **MoavenO**, Asadzadeh AghdaeeHR, GhafarzadeganK, Jami-AhmadiK Farzadnia M, AbbaszadeganMR. Clinicopathological Significance of E-cadherin, β-catenin and p53 Expression in Gastric Adenocarinoma. *J Res Med Sci* 2009; 14(4): 239-47.
4. Gholamin M, **Moaven O**, Memar M, Farshchian M, Naseh H, Malekzadeh R, Sotoudeh M Rajabi-Mashhadi MT, Forghani MN, Farrokhi F, Abbaszadegan MR. Overexpression and interactions of IL-10, TGF-β and VEGF Expression in Esophageal Squamous Cell Carcinoma. *World J Surg* 2009; 33(7):1439-45
5. GholaminM, **MoavenO**, Farshchian M, Rajabi-MashhadiMT, Mahmoudi M, SankianM, Sazegarnia M, Abbaszadegan MR.Highly Efficient GFP mRNA Transfection of Dendritic Cell: Optimization Tool for Immuno-genetherapy of Esophageal Squamous Cell Carcinoma. *Iranian Journal of Biotechnology* 2010; 8(2):121-6
6. Taghavi N, Sotoudeh M, Biramijamal F, Khademi H, Malekzadeh R, **Moaven O,** Memar B, Arabi A, Abbaszadegan MR. P16INK4a promoter hypermethylation and protein expression correlates with P53 and MDM2 overexpression in Esophageal Squamous Cell Carcinoma patients. *BMC Cancer* 2010; 10:138.
7. GholaminM, **MoavenO,** Farshchian M, Mahmoudi M, SankianM, Memar B, Rajabi-MashhadiMT, Forghani MN, Malekzadeh R, Abbaszadegan MR. Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in Esophageal Squamous Cell Carcinoma: preliminary step for DC vaccine design. *BMC Cancer* 2010, 10:261.
8. Boroumand S, Sima HR, Ghaffarzadegan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, **Moaven O**, Rajabi-Mashhadi MT, Azarian S, Mashhadinezhad M, Tavakkol Afshari J. Soluble Fas/Fas Ligand might serve as a diagnostic tool fgastric adenocarcinoma. *BMC Cancer* 2010, 10:275.
9. Taghavi N, Biramijamal F, Sotoudeh M, **Moaven O**, Khademi H, Abbaszadegan MR, Malekzadeh R. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. *World J* *Gastroenterol* 2010;16(39):4958-67
10. **MoavenO**, Raziee HR, Sima HR, Ganji A, Malekzadeh R, A’rabi A, Abdollahi A, Memar B, Setoudeh M, Naseh H, Nekoui N, Razavipour A, Gholamin M, Dadkhah E, Farshchian M, AbbaszadeganMR. Interactions of genetic polymorphisms in glutathione-s-transferase M1, T1 and P1 and increased susceptibility to esophageal cancer. *Cancer Epidemiol* 2010; 34(3):285-90
11. Raeisossadati R, Farshchian M, Ganji A, Tavassoli A, Velayati A, Dadkhah E, Chavoshi S, Mehrabi Bahar M, Memar B, Naseh H, Forghanifard MM, Moghbeli M, **Moaven O,** Abbaszadegan MR. Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients. *Int J Colorectal Dis* 2011 Oct;26(10):1265-70. Epub 2011 May 15.
12. Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, Dadkhah E, Naseh H, Moghbeli M, Raeisossadati R, Abbaszadegan MR. Cancer-testis gene profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy. *Cancer Biol Ther* 2011 Aug 1;12(3): 191-7.
13. Forghanifard MM, **Moaven O,** Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, Moghbeli M, Nejadsattari T, Parivar K, Abbaszadegan MR. Expression Analysis Elucidates the Roles of MAML1 and Twist1 in Esophageal Squamous Cell Carcinoma Aggressiveness and Metastasis. *Ann Surg Oncol.* 2012 Mar;19(3):743-9. Epub 2011 Oct 18.
14. Moghbeli M, Moaven **O**, Dadkhah E, Farzadnia M, Mohamadian RoshanN, Asadzadeh-aghdaeeH, Naseh H, Mehrabi BaharM, Abbaszadegan MR. High frequency of microsatellite instability in sporadic colorectal cancer patients in northeastern Iran. *Genet Mol Res* 2011 Dec 14;10(4)
15. **Moaven O**, Hodin RA. Chilaiditi Syndrome: A Rare Entity with Important Differential Diagnoses. *Gastroenterol Hepatol* 2012 Apr:8(4):276-8.
16. Moss AK, Hamarneh SR, Mohamed MM, Ramasamy S, Yammine H, Patel P, Kaliannan K, Alam SN, Muhammad N, **Moavan O**, Teshager A, Malo NS, Narisawa S, Millan JL, Warren HS, Hohmann E, Malo MS, Hodin RA. Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. *Am J Physiol Gastrointest Liver Physiol*. 2013 15;304(6):G597-604
17. Abbaszadegan MR, Hassani S, Vakili R, Saberi MR, Baradaran-Heravi A, A'rabi A, Hashemipour M, Razzaghi-Azar M, **Moaven O**, Baratian A, Ahadian M, Keify F, Meurice N. Two novel mutations in CYP11B1 and modeling the consequent alterations of the translated protein in classic congenital adrenal hyperplasia patients. *Endocrine*. 2013 Aug;44(1):212-9.
18. Kaliannan K, Economopoulos KP, Hamarneh SR, Alam SN, **Moaven O**, Patel P, Malo NS, Ray M, Abtahi SM, Muhammad N, Raychowdhury A, Teshager A, Mohamed MMR, Moss AK, Ahmed R, Hakimian S, Narisawa S, Millán JL, Hohmann E, Warren HS, Bhan AK, Malo MS, Hodin RA. Intestinal alkaline phosphatase prevents the metabolic syndrome in mice. *Proc Natl Acad Sci U S A*. 2013 110(17):7003-8.
19. Moghbeli M, **Moaven O**, Memar B, Raziei HR, Aarabi A, Dadkhah E, Forghanifard MM, Manzari F, Abbaszadegan MR. Role of hMLH1 and E-Cadherin Promoter Methylation in Gastric Cancer Progression*. J Gastrointest Cancer*. 2014 Mar;45(1):40-7
20. Alam SN, YammineH, **Moaven O**, Ahmed R, Moss AK, Biswas B, Mohammad N, Biswas R, Raychowdhury A, KanakarajuK, Ghosh S, Ray M, HamarnehS, Barua S, Bhan AK, Malo MS, Hodin RA. Intestinal Alkaline Phosphatase Prevents Antibiotic-Induced Susceptibility to Enteric Pathogens. *Ann Surg.* 2014 Apr;259(4):715-22
21. Malo MS, **Moaven O**, Muhammad N, Biswas B, Alam SN, Economopoulos KP, Gul SS, Hamarneh SR, Malo NS, Teshager A, Mohamed MM, Tao Q, Narisawa S, Millan JL, Hohmann EL, Warren HS, Robson SC, Hodin RA. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. *Am J Physiol Gastrointest Liver Physiol.* 2014 May 15;306(10):G826-38.
22. Kahkhaie KR, **Moaven O**, Abbaszadegan MR, Montazer M, Gholamin M. Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer. *World J Surg*. 2014 Aug;38(8):2052-7
23. Forghanifard MM, Gholamin M, **Moaven O**, Farshchian M, Ghahraman M, Aledavood A, Abbaszadegan MR. Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. *Med Oncol*. 2014 Oct;31(10):191.
24. Economopoulos KP, Ward NL, Phillips CD, Teshager A, Patel P, Rafat Mohamed MM, Hakimian S, Cox SB, Ahmed R, **Moaven O**, Kaliannan K, Alam SN, Haller JF, Goldstein AM, Bhan AK, Malo MS, Hodin RA. Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase. *Diabetes Obes Metab*. 2016;18(5):519-27
25. **Moaven O**, Raziee H, Bowne W, Abbaszadegan MR, Fuchs B. Disease Biomarkers in Gastrointestinal Malignancies. *Disease Markers.* 2016;2016:4714910
26. **Moaven O,** Bland K. Triple negative breast cancer: What surgeons should know*.* *Clin Surg*. 2016; 1: 1283
27. Lally JS, Ghoshal S, DePeralta DK, **Moaven O**, Wei L, Masia R, Erstad D, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, Bates J, Sun H, Wang T, Liu H, Ray AS, Saha AK, Greenwood J, Bhat S, Harriman G, Miao W, Rocnik JL, Westlin WF, Muti P, Tsakiridis T, Harwood HJ, Kapeller R, Hoshida Y, Tanabe KK, Steinberg GR, Fuchs BC. Inhibition of acteyl-CoA carboxylase by phosphorylation or by the liver-specific inhibitor, ND-654, is vital for restraining lipogenesis and hepatocellular carcinoma. *Cell Metab.* 2019 Jan 8;29(1):174-182.e5.
28. **Moaven O**, Richman JS, Reddy S, Wang T, Heslin MJ, Contreras CM. Healthcare disparities in outcomes of patients with resectable pancreatic cancer. *Am J Surg. 2019 Apr;217(4):725-731*
29. **Moaven O**, Wang TN. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. *Surg Clin North Am.* 2019 Jun;99(3):479-499.
30. **Moaven O**. Invited Commentary on "Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis". *Int J Surg.* 2019 Dec;72:91. doi: 10.1016/j.ijsu.2019.10.035.
31. **Moaven O**, Votanopoulos KI, Shen P, Mansfield P, Bartlett DL, Russell G, McQuellon R, Stewart JH, Levine EA.  Health-Related Quality of Life after Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Caner: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. *Ann Surg Oncol*. 2020 Mar;27(3):772-780
32. **Moaven O**, Perry KC, Votanopoulos KI, Shen P, Levine EA. ASO Author Reflections: Patient-Reported Outcomes of Mucinous Appendiceal Cancer Improve with Oxaliplatin HIPEC. *Ann Surg Oncol.* 2020 Mar;27(3):781-782
33. Mangieri CW, Kuncewitch M, Fowler B, Erali RA, **Moaven O**, Shen P, Clark CJ. Surgical Drain Placement in Distal Pancreatectomy is Associated with an Increased Incidence of Post-Operative Pancreatic Fistula and Higher Readmission Rates. *J Surg Onc* 2020 Jul 2. doi: 10.1002/jso.26072. Online ahead of print.
34. Forsythe S, Sasikumar S, **Moaven O**, Sivakumar HM, Shen P, Levine E, Skardal A, Votanopoulos KI. Personalized Identification of The Optimal HIPEC Perfusion Protocol in A Patient-Derived Tumor Organoid Platform.*Ann Surg Oncol*. 2020 Dec;27(13):4950-4960.
35. Forsythe S, **Moaven O**, Votanopoulos KI. ASO Author Reflections: Patient-Derived Tumor Organoids—A Platform for a Precision Approach for Peritoneal Malignancies. *Annals of Surgical Oncology* 2020 Dec;27(13):4961-4962
36. **Moaven O**, Su J, Jin G, VotanopoulosKI, ShenP, MangieriC, ChouJ, O’NeillSS, PerryKC, MillerLD, LevineEA. Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. *Ann Surg Oncol* 2020 Dec;27(13):5016-5023.
37. **Moaven O**, MillerLD, LevineEA. ASO Author Reflectios: Molecular Profiling Can Provide Personalized Clinical Guidance in The Management of Peritoneal Malignancies.*Annals of Surgical Oncology* 2020  Dec;27(13):5024-5025.
38. Mangieri CW, Strode MA, **Moaven O**, Clark CJ, Shen P. Utilization of Radiation Therapy Provides Strongest Protective Effect for Avoidance of Post-Operative Pancreatic Fistula following Pancreaticoduodenectomy: A NSQIP Analysis. *J Surg Oncol*. 2020 Dec;122(8):1604-1611.
39. Shuford RA, Cairns AL, **Moaven O**. [Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment.](https://www.ncbi.nlm.nih.gov/pubmed/33238500/)*Cancers*. 2020 Nov 23;12(11). doi: 10.3390/cancers12113481.
40. Mangieri CW, **Moaven O**, Votanopoulos KI, Shen P, Levine EA. Quality Analysis of Operative Reports and Referral Data for Appendiceal Peritoneal Carcinomatosis. *Surgery*. 2021 Apr;169(4):790-795.
41. **Moaven O**, MangieriCW, Stauffer JA, Anastasiadis PZ, Borad MJ. Evolving role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. *JCO Precis Oncol.* 2021 Feb 24;5:PO.20.00395. doi: 10.1200/PO.20.00395.
42. Stewart JH, Blazer DG, Godoy Calderon MJ, Carter TM, Eckhoff A, Al Efishat MA, Fernando DG, Foster JM, Hayes-Jordan A, Johnston F, Lautz TB, Levine EA, Maduekwe UN, Mangieri CW, **Moaven O**, Mogal H, Shen P, Votanopoulos KI. The Evolving Management of Peritoneal Surface Malignancies. *Curr Probl Surg*. 2021 Apr;58(4):100860.
43. **Moaven O**, MangieriCW, Stauffer JA, Anastasiadis PZ, Borad MJ. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. *JCO Precis Oncol*. 2021 Apr 27;5:PO.21.00003. doi: 10.1200/PO.21.00003.
44. **Moaven O,** Katz MHG, Snyder RA. Role of Radiation In The Treatment of Pancreatic Adenocarcinoma in the Neoadjuvant Setting. *American College of Surgeons Bulletin,* Sep 2; 2021
45. **Moaven O**, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, Shen P. Optimal Adjuvant Treatment Approach after Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based On Pathologic Features. [*Ann Surg*.](https://www-ncbi-nlm-nih-gov.go.libproxy.wakehealth.edu/pubmed/31913868) 2021 Dec 1;274(6):1058-1066.
46. Mangieri CW, **Moaven O**, Valenzuela CD, Erali RA, Votanopoulos KI, Shen P, Levine EA. [Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.](https://pubmed.ncbi.nlm.nih.gov/34841542/) *J Surg Oncol.* 2022 Mar;125(4):703-711.
47. Mangieri CW, **Moaven O**, Valenzuela CD, Erali RA, Votanopoulos KI, Shen P, Levine EA. [Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.](https://pubmed.ncbi.nlm.nih.gov/35022900/) *Ann Surg Oncol*. 2022 Apr;29(4):2641-2648.
48. Lundy ME, **Moaven O**, Perry KC, Mangieri CW, Valenzuela CD, Russell GB, Bordelon R, Shen P, Votanopoulos KI, Levine EA. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Cancer with Peritoneal Dissemination: 30 Years of Experience at a Single Institution. *J Am Coll Surg.* 2022 Apr 1;234(4):546-556.
49. Valenzuela CD, Levine EA, Mangieri CW, Gawdi R, **Moaven O**, Russell G, Lundy ME, Perry KC, Votanopoulos KI, Shen P. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience. *Ann Surg Oncol.* 2022 Jun;29(6):3436-3445.
50. Valenzuela CD, **Moaven O**, Gawdi R, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AW, Cha C, Mangieri CW, Zarandi NP, Dourado J, Perry KC, Russell G, Shen P. Association of Primary Tumor Laterality with Surgical Outcomes for Colorectal Liver Metastases: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC). *HPB (Oxford).* 2022 Feb 28:S1365-182X(22)00066-1. doi: 10.1016/j.hpb.2022.02.006.
51. Gawdi R, Valenzuela CD, **Moaven O,** Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Russell G, Zarandi N, Dourado J, Shen P. Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC). *J Surg Oncol*. 2022 Apr 16. doi: 10.1002/jso.26893

**Book Chapters:**

1. **Moaven O**. Intestinal Alkaline Phosphatase. In: Schwab M. (Ed.) *Encyclopedia of Cancer*: SpringerReference ([www.springerreference.com](http://www.springerreference.com)). Springer-Verlag Berlin Heidelberg, 2015. DOI: 10.1007/978-3-642-27841-9\_7126-15
2. **Moaven O**. Chen H. Medullary Thyroid Cancer. In: Dimick JB, Upchurch GR, Sonnenday CJ, Kao L. *Clinical Scenarios in Surgeries: Decision Making and Operative Technique 2018* 2nd edition.
3. **Moaven O**, Contreras CC*.* Nature and Clinical Impact of Physiologic Changes Associated with Aging. In: Ashley SW. (Ed) In: *Scientific American Surgery. 2018*
4. **Moaven O**, Shen P, Levine EA, Votanopoulos KI. Current Evidence for the Management of Appendiceal Cancer with Peritoneal Surface Dissemination. *Current problems in surgery 2020* doi:https://doi.org/10.1016/j.cpsurg.2020.100860.

**Published Abstracts and Scientific Presentations:**

1. **Moaven O**, Sima H, Ghafarzadegan K, Arabi A, Mashhadinejad A, Sajadi M, Esmaeeli E, Jafarzadeh M, Abbaszadegan MR. A. p16 Hypermethylation and protein expression in Gastric Cancer and Its Relationship with Demographic and Histopathologic Features. *Govaresh, 2007; 12(Supp): 14-15. The 6th Iranian Congress of Gastroenterology and Hepatology (ICGH7), Tehran, 2007.*
2. **MoavenO**, Raziee HR, Arabi A, MavvajiB, AbbaszadeganMR. Genetic Polymorphism in Glutatione-S-Transferase T1, P1 and M1 and susceptibility to esophageal cancer: First study in Iranian Population. *Int J hematology oncol BMT* 2007; 4 (supp 1):143 *The 19th Asia Pacific Cancer Congress (APCC), Tehran, 2007*
3. Jafarzadeh M, Sima HR, Shandiz EE, Hosseinnezhad H, Ghafarzadegan K, Raziee H, Abdollahi T, Ghadri S, Bahrani M, **Moaven O**. Expression of cell adhesion molecule CD44 in diffuse and intestinal type of gastric adenocarcinoma and its relationship with metastasis. *Gastroenterology 2008; 134(4): A445.*

*DDW2008 San Diego, USA, 2008*

1. AbbaszadeganMR, Gholamin M, Malekzadeh R, Sankian M, Memar B, Forghani M, Rajabi MT, **Moaven O**, Farshchian M, Ghavamnasiry MR. Frequent Immune Escape in Esophageal Squamous Cell Carcinoma (ESCC) Makes a suitable Target for Gene transfer Immunotherapy *American Association of Cancer Research International Conference on Advances in Cancer Research, Jordan, 2008.* Travel award winner
2. **Moaven O**, Sima HR, Ghafarzadegan K, Arabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M Esmaeeli Shandiz E, Abbaszadegan MR. Hypermethylated Circulating Tumoral DNA Might Serve as an Early Diagnostic Tool for Esophageal and Gastric Carcinoma. *American Association of Cancer Research. International Conference on Advances in Cancer Research, Jordan, 2008.* Travel award winner
3. Abbaszadegan MR, **Moaven O**, Sima HR, Ghafarzadegan K, A'rabi A, Forghani MN, Raziee HR. A useful serum marker for early detection of gastric cancer, Aberrant p16 methylation. *American Association for Cancer Research. Candidate Pathways, Whole Genome Scan, Reconciling Results, Looking into the Future. USA, 2008*
4. **Moaven O**, Sima HR, Ghafarzadegan K, Arabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M Esmaeeli Shandiz E, Abbaszadegan MR. Hypermethylated Circulating Tumoral DNA Might Serve as an Early Diagnostic Tool for Esophageal and Gastric Carcinoma. *GI Cancer Symposium, ASCO, San Francisco, CA, 2009*
5. Afshari TJ, Sima H, Ghafarzadegan K, Mokhtarifar A, Shandiz EE, Jafarzadeh M, Hosseinnezhad H, Bahrani M, **Moaven O**, Ghadri S, Abdolahi T. DQB1 and its distribution in gastric adenocarcinoma: The first report from Iran. *Annals of Oncology, 2008; 19(Supp 6): 32-33.*

*10th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2008*

1. **MoavenO**, Raziee HR, A’rabi A, Nekuee N, AbbaszadeganMR. Interactions of genetic polymorphisms in glutathione-s-transferase M1, T1 and P1 and increased susceptibility to esophageal cancer. *American Association of Cancer Research*. *Frontiers in Cancer Prevention Research*, *DC, 2008*
2. Taghavi N, Biramijamal F, Sotoudeh M, Khademi H, Malekzadeh R, **Moaven O**, Memar B, A’rabi A, Abbaszadegan MR. P16INK4a promoter hypermethylation and protein expression correlates with P53 and MDM2 overexpression in Esophageal Squamous Cell Carcinoma patients. American Association of Cancer Research*, MOLECULAR TARGETS and CANCER THERAPEUTICS, Boston, MA*, *November 15-19, 2009*
3. Forghanifard MM, Farshchian M, Gholamin M, Dadkhah E, **Moaven O,** Abbaszadegan MR. A new specific biomarker for tumor in esophageal squamous cell carcinoma. *American Association of Cancer Research, MOLECULAR TARGETS and CANCER THERAPEUTICS, Boston, MA*, *November 15-19, 2009*
4. Ghaffarzadehgan K, Abdolahi T, Ghadri S, Hosseinnezhad H, **Moaven O**, Saeedi R, Sima HR. Expression of angiogenic marker CD34 in gastric adenocarcinoma and its relationship with cliniclopathological characteristics. *International Immunology Meeting Abstracts 2010; 22 (Supp 1):iii167*

*14th International Congress of Immunology, Japan, 2010*

1. Gholamin M, **Moaven O**, Memar M, Farshchian M, Naseh H, Abbaszadegan MR. Overexpression and interactions of IL-10, TGF-β and VEGF Expression in Esophageal Squamous Cell Carcinoma. *American Association of Cancer Research. International Conference on Advances in Cancer Research, Jordan, 2010.* Travel award winner
2. **MoavenO**, Raziee HR, Sima HR, Ganji A, A’rabi A, Abdollahi A, Memar B, Naseh H, Gholamin M, AbbaszadeganMR. Interactions of genetic polymorphisms in glutathione-s-transferase M1, T1 and P1 and increased susceptibility to esophageal cancer. *American Association of Cancer Research. International Conference on Advances in Cancer Research, Jordan, 2010.* Travel award winner
3. **MoavenO**, MoghbeliM, Dadkhah E, FarzadniaM, Mohamadian RoshanN, Asadzadeh-aghdaeeH, Mehrabi BaharM, Raesossadati R, Forghanifard MM, Abbaszadegan MR. High frequency of microsatellite instability in sporadic colorectal cancer patients in northeastern Iran. *Ninth Annual AACR International Conference on Frontiers in Cancer Prevention Research, Philadelphia, 2010*
4. **MoavenO**, GholaminM, Farshchian M, Mahmoudi M, SankianM, Memar B, Forghani MN, Malekzadeh R, Abbaszadegan MR. Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in Esophageal Squamous Cell Carcinoma: preliminary step for DC vaccine design. *Cancer Res April 15, 2010 70:4752; doi:10.1158/1538-7445.AM10-4752. 101 Annual meeting American Association of Cancer Research. DC, 2010*
5. Abbaszadegan MR, Saidi R, **Moaven O**, A'rabi A, Homaei- Shandiz F, Noferesti GH. Familial Esophageal Squamous Cell Carcinoma and Breast cancer in several Pedigrees with BRCA2 Mutations. *European Journal of Human Genetics 2011; 19 (supp 2):207*

*European Human Genetics Conference, Netherland, 2011*

1. Alam SN, Yammine H, Ahmed R, Hamarneh SR, Economopoulos KP, **Moaven O**, Kaliannan K, Moss AK, Ray M, Muhammad N, Mohamed M, Raychowdhury A, Barua S, Bhan AK, Malo MS, Hodin RA. Oral Supplementation With Intestinal Alkaline Phosphatase: A Novel Therapy to Treat Salmonella Colitis. *Gastroenterology 2012; 142(5): Supp1;S-692*

*DDW 2012 San Diego, USA.*

1. Ahmed R, Alam SN, Economopoulos KP, **Moaven O**, Ray M, Kaliannan K, Hamarneh SR, Muhammad N, Barua S, Raychowdhury A, Mohamed M, Bhan AK, Malo AK, Hodin RA. Prevention of Antibiotic-Associated DSS Colitis by Intestinal Alkaline Phosphatase. *Gastroenterology 2012; 142(5): Supp1;S-393*

*DDW 2012 San Diego, USA.*

1. Kaliannan K, Alam SN, **Moaven O**, Moss AK, Ray M, Ahmed R, Hamarneh SR, Muhammad N, Economopoulos KP, Mohamed M, Bhan AK, Malo MS, Hodin RA. The Effects of Orally Administered Intestinal Alkaline Phosphatase on High- Fat Diet-Induced Metabolic Disorders. *Gastroenterology 2012; 142(5): Supp1;S-613*

*DDW 2012 San Diego, USA.*

1. Ray M, **Moaven O**, Alam SN, Ahmed R, Kaliannan K, Hamarneh SR, Muhammad N, Economopoulos KP, Mohamed M, Malo MS, Hodin RA. Identification of Lipoteichoic Acid as a New Target for Intestinal Alkaline Phosphatase. *Gastroenterology 2012; 142(5): Supp1;S-861*

*DDW 2012 San Diego, USA.*

1. **Moaven O**, Alam SN, Ray M, Kaliannan K, Ahmed R, Hamarneh SR, Economopoulos KP, Moss AK, Muhammad N, Mohamed M, Malo MS, Hodin RA. A Novel Function of Intestinal Alkaline Phosphatase as an Endogenous Prebiotic*. Gastroenterology 2012; 142(5): Supp1;S-125*

*Digestive Disease week (DDW) 2012 San Diego, USA.*

*New England Surgical Society (NESS), Annual Resident & Fellow Research Day, Connecticut 2012*

1. Yammine H, Alam SN, Ramasamy S, **Moaven O**, Ahmed R, Moss AK, Bhan AK, Malo MA, Hodin RA. Oral supplementation with intestinal alkaline phosphatase: A novel preventive strategy against C. difficile colitis. *Journal of the American College of Surgeons 2012; 215(3): Suppl:S48-9, 98th Annual Clinical Congress of the American-College-of-Surgeons*
2. **Moaven O,** Alam SN, Ray M, Kaliannan K, Ahmed R, Hamarneh SR, Economopoulos KP, Moss AK, Muhammad N, Mohamed M, Malo MS, Hodin RA. Intestinal Alkaline Phosphatase is an endogenous regulator of host microbiota. *Journal of the American College of Surgeons 2013; 217 (3), S14-S14*

*99th Annual Clinical Congress of the American-College-of-Surgeons*

1. **Moaven O**, Wei L, Harriman G, Greenwood J, Bhat S, Westlin WF, Harwood Jr. HJ, Kapeller R, DePeralta D, Tanabe KK, Fuchs BC. Liver Selective Acetyl-CoA Carboxylase Inhibition by ND- 654 Improves Survival in Cirrhotic Rats with Hepatocellular Carcinoma. Cancer Res *August 1, 2015;75(15 suppl):4452; doi:10.1158/1538-7445.AM2015-4452*

*106 Annual meeting American Association of Cancer Research; Philadelphia, 2015*

1. Wei L, **Moaven O,** Harriman G, Greenwood JR, Bhat SP, Westlin W, Harwood HJ, Kapeller R, Tanabe KK, Fuchs BC. Liver Selective Acetyl-CoA Carboxylase Inhibitor ND-654 Improves Sorafenib Efficacy in the Treatment of Hepatocellular Carcinoma in Cirrhotic Rats. In *HEPATOLOGY 2015 Oct 1 (Vol. 62, pp. 1153A-1153A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.*

*American Association for the Study of Liver Diseases (AASLD) 2015*

1. Harriman G, DePeralta DK, **Moaven O**, Wei L, Greenwood JR, Bhat SP, Tanabe KK, Fuchs BC, William Westlin, H. James Harwood, Rosana Kapeller Liver-Directed Allosteric Inhibitors of Acetyl-CoA Carboxylase Reduce Hepatic Steatosis and Improve Dyslipidemia in Diet-Induced Obese Rat Models and Reduce Inflammation and Fibrosis in a Cirrhotic Rat Model  
   *American Association for the Study of Liver Diseases (AASLD) 2015*
2. Westlin WF, Harwood HJ, DePeralta DK, Wei L, **Moaven O**, Greenwood J, Bhat S, Tanabe KK, Fuchs BC, Kapeller R, Harriman G. Liver-directed allosteric inhibitors of acetyl-CoA carboxylase favorably impact pathophysiology in the progression from NAFLD to NASH and Hepatocellular Carcinoma, including hepatic steatosis, inflammation, and fibrosis. *The International Liver Congress 2015, 50th annual meeting of the European Association for the Study of the Liver (EASL)*
3. **Moaven O**, Richman JM, Reddy S, Wang TM, Heslin MJ, Contreras CM. Race is not an Independent Predictor of Pancreatic Cancer Survival. *SSO Annual Meeting* 2017
4. **Moaven O**, Richman JM, Reddy S, Wang TM, Heslin MJ, Contreras CM. Better Outcomes for Surgical Resection of Pancreatic Cancer in Academic versus Nonacademic Centers. Accepted for oral presentation, *AAS* *2017 Las Vegas*
5. **Moaven O,** Xie R, Richman JM, Naftel D, Kirkin JK, Chen H. Trends and Disparities in Thyroid Cancer within a Health System, *AAS 2017 Las Vegas*
6. **Moaven O**, Richman JM, Reddy S, Wang TM, Heslin MJ, Contreras CM. Disparities in Refusing Offered Surgical Treatment in Gastrointestinal Malignancies. *SSO Annual Meeting* 2018
7. **Moaven O**, Levine E, Votanopoulos KI, Bartlett D, Shen P, Mansfield P; Russell G, Perry KC, McQuellon R, Stewart JH. Evaluation of Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. *SSO Regional Cancer Therapy 2019,* *SSO Annual Meeting* *2019*
8. **Moaven O**, Clark CJ, Russell G, Howerton R, Votanopoulos KI, Levine EA, Shen P. Outcomes of Different Adjuvant Treatment Approaches in Resectable Pancreatic Cancer: A National Cancer Database Study. *AHPBA Annual meeting 2019*
9. **Moaven O**, Su J, Jin G, Votanopoulos KI, Shen P, Mangieri C, Chou J, O’Neill SS, Perry KC, Miller LD, Levine EA. Genetic Signatures Can Identify Appendiceal Cancer Patients with Poor Outcomes Who Would Less Likely Benefit From Incomplete Cytoreduction/HIPEC. *SSO Advanced Cancer Therapy 2020,* *SSO Annual Meeting* *2020*
10. **Moaven O**, Clark CJ, Russell G, Mangieri C, Howerton R, Votanopoulos KI, Levine EA, Shen P. Treatment patterns and outcomes in resected pancreatic cancers: frequent deviations from the standard of care. *AHPBA Annual meeting 2020*

**Invited Presentations and Seminars:**

|  |  |  |
| --- | --- | --- |
| 2016  Dept of Surgery, UAB | Laparoscopic Gastric Electrical Stimulator for Management of refractory Gastroparesis | Clinical conference  Aldrete Lectureship |
| 2018  Dept of Surgery, UAB | Artificial intelligence: new frontiers in transforming Surgical innovation | Grand Round |
|  |  |  |
| 2020  Dept of Surgery, Wake Forest | Artificial intelligence: new frontiers in transforming Surgical innovation | Grand Round |
| 2021  Mayo Clinic Florida | Evolving Role of Oncolytic Virotherapy in Cancer Treatment: Challenges and Prospect | Medical Grand Rounds |

**Editorial Posts and Activities**

**Journal Editor or Associate Editor:**

2015- 2016 Lead Guest Editor, Special issue on “Disease Biomarkers in Gastrointestinal Malignancies” – Disease Markers

2020- Editorial board, Topic Editor – Cancers

**Reviewer:**

2011 Reviewer – Cancer letters

2012 Reviewer – Gut

2012- Reviewer – Annals of Surgical Oncology

2013- Reviewer – International Journal of Cancer

2015- Reviewer – International Journal of Surgery

2017- Reviewer – Annals of Surgery

2018- Reviewer – Cytotherapy

2019- Reviewer – Journal of Clinical Medicine

2020- Reviewer – Diagnostics

2020- Reviewer – Cancers

2021- Reviewer- World Journal of Surgical Oncology

**SERVICE ACTIVITIES**

**University/Institutional Service**

**Departmental committees:**

2020-2021 Quality Control, Readmissions Mayo Clinic, Florida

**National Service**

**Professional society committees:**

2020 Member- GI committee, Pancreas cancer working group, Alliance for Clinical Trials

2021 Co-leader, GI Surgery working group, Alliance for Clinical Trials

2021 Member, International Relations Committee, AHPBA

**Clinical Service**

I am a surgical oncologist with clinical interest in HPB/GI malignancies

**Administrative Responsibilities**

**Interdisciplinary/other program (center or program):**

Establishing the **EMPOWER Program**: Evaluation, Multimodality Prehabilitation and Oncology support: a Well-being Enhancement Resource. This multidisciplinary program is focused on prehabilitation of patients with HPB/GI malignancies who undergo neoadjuvant treatment with intention for curative resection. This multidisciplinary program is designed to improve functional capacity (physical exercise) nutritional status and psychosocial support in the preoperative period while on systemic treatment.